Alexandria Real Estate Equities Balances Strength With Strain

Alexandria Real Estate Equities ((ARE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Alexandria Real Estate Equities’ latest earnings call struck a cautious but constructive tone. Management highlighted strong liquidity, long-dated debt, disciplined G&A cuts, and a reaffirmed FFO outlook, even as they acknowledged sharp pressure from lower occupancy, weaker same-property NOI, and softer rents that will test execution over the next several quarters.

FFO Results and 2026 Outlook

Alexandria reported first-quarter 2026 FFO per share diluted as adjusted of $1.73, and reaffirmed its full-year 2026 FFO midpoint at $6.40 while tightening the range. Fourth-quarter 2026 FFO guidance was narrowed to $1.40–$1.50, with the $1.45 midpoint trimmed by just $0.05, reflecting modest pressure rather than a reset.

Balance Sheet Strength and Liquidity Cushion

The company emphasized a “tremendous” $4.2 billion liquidity position and the longest average remaining debt maturity among S&P 500 REITs at about 10 years. A recent unsecured bond tender generated a $366 million gain and helped reduce overall debt, supporting a 4Q 2026 net debt to annualized adjusted EBITDA target of 5.6–6.2x, down from the current 6.8x.

Disposition-Driven Capital Recycling Strategy

Management detailed a sizable capital recycling plan centered on $2.9 billion of 2026 dispositions and partial interest sales at the midpoint. Roughly 80% of that amount is already pending or identified, with the mix skewed toward core, noncore, and JV assets and 10–25% land, making execution of this program key to funding growth and deleveraging.

Leasing Momentum in Development and Redevelopment

Development and redevelopment activity showed some traction, with about 394,000 square feet of leasing and LOIs, including 118,000 square feet of executed leases and 276,000 square feet in signed LOIs. Management expects 1.1 million square feet of previously vacant space to commence around September and early second-quarter trends point to roughly 900,000 square feet of leasing volume.

Market Share Gains and Mega Campus Advantage

Alexandria reported leasing outperformance in its largest clusters, led by Greater Boston capturing around 20% of total leases, San Francisco Bay about 30%, and San Diego roughly 67%, each well above the company’s local market share. Management underscored that mega campuses now account for 78% of total annual rental revenue, reinforcing the strategic focus on scale locations.

Tenant Quality and Lease Economics

The REIT highlighted its high-quality rent roll, with 55% of annual rental revenue coming from investment-grade or large-cap public tenants and roughly 80% of the top 20 tenants fitting that profile. Those top tenants carry a nearly 10-year weighted average lease term, while rent escalators near 3% on 97% of leases helped support an adjusted EBITDA margin of 66% in the quarter.

G&A Discipline and Expense Savings

Corporate overhead remains a bright spot, as G&A expenses fell by $7.4 million versus the 2024 quarterly average. Alexandria reiterated its 2026 G&A guidance of $134–$154 million, implying roughly 14% savings at the midpoint versus 2024 and about $76 million of total savings across 2025 and 2026, leaving G&A at a lean level versus peers.

Development Pipeline and Future Deliveries

The company has 1.9 million square feet under construction that is already 77% leased, with around 600,000 square feet expected to stabilize in 2026 at a robust 93% leased. Another 1.6 million square feet across five projects is under strategic review through 2027, giving management flexibility to pace capital deployment and align with market demand.

Record Valuation Highlights Asset Quality

In a notable validation of portfolio value, Alexandria closed the sale of 409/499 Illinois Street in Mission Bay at $1,645 per square foot, the highest price ever achieved for a lab asset in San Francisco. The property was only 40% occupied, underscoring investor appetite for top-tier life science real estate even amid industry turbulence.

Occupancy Slippage and Near-Term Pressure

Portfolio occupancy fell sharply to 87.7% at quarter end, a 320 basis-point drop from the prior quarter, and guidance for year-end 2026 occupancy was cut from 88.5% to 87%. Management attributed the change in part to retaining certain assets with vacancy and expected downtime, signaling that filling space will be a key challenge this year.

Same-Property NOI and Earnings Headwinds

Same-property NOI declined 11.9% year over year, or 11.7% on a cash basis, largely due to lower occupancy and downtime. The company now expects full-year same-property NOI to fall 9.5% at the midpoint, a one-point worsening that reflects heavier short-term earnings drag from vacancies.

Lease Expirations and Vacancy Wave

About 657,000 square feet of key leases expired and went vacant in the quarter, with another roughly 747,000 square feet of important expirations expected to do the same in 2026. Looking further out, management flagged roughly 1.5 million square feet of 2027 expirations tied to about $97 million of annual rent that are likely to experience downtime, highlighting a prolonged re-leasing cycle.

Public Biotech Weakness and Demand Mix

The company reported zero leases with public biotech tenants in the quarter, a first in its history, underlining the funding stress in that segment. Public biotechs still account for about 24% of annual rent, so a sluggish capital market for these companies remains a meaningful demand risk for Alexandria’s life science portfolio.

Rental Rate Pressure on Renewals

Rental economics softened, with free rent and rate changes under pressure and one 48,000 square foot lease at 40 Arsenal Watertown driving roughly a 15% reduction in rental rates, or 15.8% on a cash basis. Reflecting this reality, management reduced rental rate change assumptions by about 7%, and by roughly 3% on a cash basis, in its guidance.

Tenant Credit Risk and Reserves

Alexandria increased its reserve for tenant wind-downs and credit risk from around $23 million to a range of roughly $25–$30 million. The move signals a cautious stance on tenant health as life science and biotech companies navigate tighter funding conditions and shifting regulatory dynamics.

Leverage Trends and Disposition Dependence

Quarterly annualized net debt to adjusted EBITDA climbed to 6.8x, with management reiterating plans to bring that ratio down in the back half of 2026. Execution of the $2.9 billion disposition and partial interest sale program is central to this deleveraging path, making transaction timing a key swing factor for balance sheet progress.

Regulatory and Market Backdrop

Management also cited broader industry headwinds such as uncertainty at key health agencies, temporary funding policy noise, and competitive pressure from China, along with selective public equity markets that limit funding for many biotechs. These factors collectively contribute to slower leasing decisions and a more cautious demand environment for lab space.

Earnings Sensitivity to Capitalized Interest

The company noted that lower capitalized interest is now a modest drag on earnings, with reduced assumptions trimming about $0.05 from the fourth-quarter FFO midpoint and cutting guidance by $5 million at the midpoint. This underscores how FFO is increasingly sensitive to the timing of project completions and disposition milestones as development capital rolls off.

Forward-Looking Guidance and Key Milestones

Looking ahead, Alexandria reaffirmed its 2026 FFO per share midpoint at $6.40 and guided fourth-quarter FFO to $1.40–$1.50, while acknowledging softer same-property NOI and occupancy targets. Management expects leasing to pick up with roughly 900,000 square feet in the second quarter, 1.1 million square feet of leased space commencing around September, and leverage trending down toward 5.6–6.2x by year-end as $2.9 billion of planned asset sales progress.

Alexandria’s earnings call painted a picture of a high-quality life science REIT leaning on strong liquidity, valuable campuses, and disciplined costs to navigate a difficult leasing and funding cycle. For investors, the story now hinges on whether leasing momentum, asset sales, and disciplined capital allocation can offset vacancy, rent pressure, and sector headwinds without forcing a deeper reset to earnings expectations.